New Drug Combination Shows Promising Activity in Non-Small Cell Lung Cancer Patients

Patients with non-small cell lung cancer (NSCLC) now have more improved treatment options compared to standard of care with the addition of several new agents called immune-checkpoint inhibitors (ICI). Despite these changes, many patients still develop progressive disease after ICI treatment. In a new study published in Clinical Cancer Research, Moffitt Cancer Center researchers describe promising results from an early clinical trial that may offer patients who progress after ICI an additional treatment option.

Boehringer Ingelheim and MD Anderson form unique virtual research and development center to rapidly advance new cancer therapies

Boehringer Ingelheim and MD Anderson have announced a new multi-year partnership to conduct collaborative research, combining the drug-development capabilities of MD Anderson with the pipeline of novel medicines from Boehringer Ingelheim.

Leading Health Organizations Introduce New Award to Advance Lung Cancer Research

The Society of Thoracic Surgeons—along with its charitable arm, The Thoracic Surgery Foundation (TSF)—and the American Lung Association have established a new grant, the Lung Cancer Research Award, designed to support investigators performing impactful lung cancer research.